Paris-based digital health start-up Klineo has raised €2m ($2.1m) to expand its AI patient recruitment platform to include more types of cancer.  

Klineo’s platform is designed to connect healthcare professionals and patients to clinical trials. Offering two separate interfaces, patients can search for clinical trials and directly contact participating centres.

The platform also provides real-time updates on clinical trials in France and matches patients with relevant studies.  

The startup was founded in 2021 by a medical oncologist from the Gustave Roussy Institute in Paris, France, and two engineers. In 2022, Klineo launched the first national platform in France for triple-negative breast cancer in collaboration with patient association, the Collectif Triplettes Roses. This was funded by an incubator/accelerator round by ParSante Campus in 2022. The company extended the platform the following year to include new cancers, including skin cancer and lymphoma. 

With the €2m from Benta Pharma Industries (BPI) and business angels, Klineo said it plans to cover all cancers in France by the end of 2024, expanding to lung cancer and eventually to other countries and diseases. The funds will also support team expansion and platform enhancements. 

According to the American Society of Clinical Oncology Education, only 5% of cancer patients take part in clinical trials, even though 70% would be willing to participate if they knew about them.  

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Difficulties in trial recruitment is one of the key factors that can lead to trial failures. This potential financial loss has been an incentive for some companies to implement AI into the initial stages of its clinical trials.  

Additionally, patient recruitment is usually the most time-consuming stage of a clinical trial. Sponsors must find and identify a set of subjects, gather information, and use inclusion/exclusion criteria to filter and select participants.  

According to GlobalData forecasts, the AI market was worth $81.8bn globally in 2022. By 2027, it will have grown at a compound annual growth rate (CAGR) of 31.6% to $323.3bn. 

GlobalData is the parent company of Clinical Trials Arena.

In the announcement accompanying the funding, Klineo’s co-founder Arnaud Bayle said: “Today, too few patients benefit from a clinical trial because the search for one is a very tedious process. At Klineo, we offer a reliable, intuitive, and fast solution that finally gives doctors and patients, wherever they are treated, the possibility of easily finding new therapeutic options adapted to each situation, and which ultimately enables medical research to progress.”